PubMedCrossRef 5. Baumann M, Krause M, Zips D, Petersen C, Dittmann K, Dörr W, Rodemann

HP: Molecular targeting in radiotherapy of lung cancer. Lung Cancer 2004, 45:S187–197.PubMedCrossRef 6. Määttä AM, Tenhunen A, Pasanen T, Meriläinen O, Pellinen R, Mäkinen K, Alhava E, Wahlfors J: Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol 2004, 24:943–949.PubMed 7. Nemunaitis LY2603618 chemical structure J, Vorhies JS, Pappen B, Senzer N: 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther 2007, 14:762–763.PubMedCrossRef 8. Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T: Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther 2004, 10:1051–1058.PubMedCrossRef 9. Ulasov IV, Zhu ZB, Tyler MA, Romidepsin research buy Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS: Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor

activity in established intracranial glioma. Hum Gene Ther 2007, 18:589–602.PubMedCrossRef 10. Strazisar M, Mlakar V, Glavac D: The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). Cell Mol Biol Lett 2009, 14:442–4569.PubMedCrossRef 11. Ji X, Zhang J, Cheng L, Wei F, Li H, Liu X, Chen X, Li C, Wang Y, Huang Q: Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 2009, 89:193–199.PubMedCrossRef 12.

Huang Q, Zhang X, Wang H, Yan B, Kirkpatrick J, Dewhrist MW, Li CY: A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Meloxicam Clin Cancer Res 2004, 10:1439–1445.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions JFZ carried out most of the experiments and organized data for manuscript. FW, HPW, HML, XFC performed some experiments involving in viral construction, package, Western blot or cell culture. WQ and PKR participated in data organization and manuscript drafting. QH performed project design and manuscript writing. All authors read and approved the final manuscript.”
“Introduction Pancreatic cancer is one of the most virulent CYC202 malignances, with an overall 5-year survival rate of only 3-5% and a median survival time after diagnosis of less than 6 months[1]. This highly lethal disease is usually diagnosed in an advanced stage, when there are few or no effective therapies[2]. Even among patients undergoing a potentially curative resection, the long-term outcome remains unsatisfactory because of early recurrence and metastatic disease[3]. Despite the immensity of the clinical problem, the biology of pancreatic cancer remains only poorly understood.